Analysis of CYP2D6 genotype and response to tetrabenazine
- 26 December 2012
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 28 (2) , 210-215
Abstract
Tetrabenazine is effective in the treatment of the chorea associated with Huntington disease and other hyperkinetic movement disorders. Following oral administration, tetrabenazine is hepatically transformed into 2 active metabolites that are CYP2D6 substrates. There are 4 CYP2D6 genotypes: poor metabolizers, intermediate metabolizers, extensive metabolizers, and ultrarapid metabolizers. CYP2D6 genotyping was performed on sequential subjects treated with tetrabenazine, but results were not known at the time of titration. Duration of titration to a stable dose, total daily dose, response rating scores, and adverse events were retrospectively collected and subsequently analyzed. Of 127 patients, the majority (n = 100) were categorized as extensive metabolizers, 14 as intermediate metabolizers, 11 as poor metabolizers, and 2 as ultrarapid metabolizers. Ultrarapid metabolizer patients needed a longer titration (8 vs 3.3, 4.4, and 3 weeks, respectively; P < .01) to achieve optimal benefit and required a higher average daily dose than the other patients, but this difference did not reach statistical significance. The treatment response was less robust in the intermediate metabolizer group when compared with the extensive metabolizer patients (P = .013), but there were no statistically significant differences between the various groups with regard to adverse effects. Our findings demonstrate that, aside from the need for a longer titration in the ultrarapid metabolizers, there are no distinguishing features of patients with various CYP2D6 genotypes, and therefore the current recommendation to systematically genotype all patients prescribed more than 50 mg/day of tetrabenazine should be reconsidered. © 2012 Movement Disorder SocietyKeywords
This publication has 34 references indexed in Scilit:
- The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1The AAPS Journal, 2011
- Genomics and Drug ResponseNew England Journal of Medicine, 2011
- Effects ofCYP2C19Genotype on Outcomes of Clopidogrel TreatmentNew England Journal of Medicine, 2010
- Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD InvestigatorsBMC Neurology, 2009
- TetrabenazineExpert Opinion on Pharmacotherapy, 2009
- Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patientsThe Pharmacogenomics Journal, 2009
- Tetrabenazine therapy of pediatric hyperkinetic movement disordersMovement Disorders, 2006
- Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and futureTrends in Pharmacological Sciences, 2004
- Inheritance and Drug ResponseNew England Journal of Medicine, 2003
- Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic InteractionsClinical Pharmacokinetics, 1997